Feedback / Questions
TerraCoV2 - Oragenics, National Institute of Allergy and Infectious Diseases
https://www.businesswire.com/news/home/20210309005395/en/Oragenics-Enters-into-Material-Transfer-Agreement-with-Biodextris-for-Mucosal-Adjuvant-for-Intranasal-COVID-19-Vaccine
Mar 9, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next